Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: Results from the randomized VOYAGE 1 trial
Journal of the European Academy of Dermatology and Venereology | Mar 10, 2018
Most read this week
Journal of the European Academy of Dermatology and Venereology | Mar 10, 2018